Scott L Armstrong

US Patent:

20110106207, May 5, 2011

Filed:

Nov 2, 2009

Appl. No.:

12/611110

Inventors:

Lawrence J Cauller - Plano TX, US
Scott Armstrong - Austin TX, US

International Classification:

A61N 1/34

US Classification:

607 46

Abstract:

Methods, devices and systems for neural stimulation using a short-pulse stimulation are described. Using a waveform that generates a sufficiently large capacitive current density in the tissue surrounding a nerve allows neural stimulation at one hundredth the power of a charge injection stimulation. A capacitive discharge may be used to generate the short-pulse stimulation waveform. Short pulse stimulation may be used to generate parasthesia, particularly for treatment of chronic pain.

US Patent:

20110106219, May 5, 2011

Filed:

Nov 2, 2009

Appl. No.:

12/611105

Inventors:

Lawrence J Cauller - Plano TX, US
Scott Armstrong - Austin TX, US

International Classification:

A61N 1/36

US Classification:

607 72, 607 2

Abstract:

Methods, devices and systems for neural stimulation using a short-pulse stimulation are described. Using a waveform that generates a sufficiently large capacitive current density in the tissue surrounding a nerve allows neural stimulation at one hundredth the power of a charge injection stimulation. A capacitive discharge may be used to generate the short-pulse stimulation waveform. Short pulse stimulation may be used to generate parasthesia, particularly for treatment of chronic pain.

US Patent:

20220307031, Sep 29, 2022

Filed:

Feb 10, 2022

Appl. No.:

17/668504

Inventors:

- New York NY, US
Eneda Toska - Edgewater NJ, US
Scott Armstrong - Wayland MA, US

Assignee:

MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY

International Classification:

C12N 15/113
A61P 35/00
A61K 31/4439
A61K 31/454
A61K 31/713
A61K 45/06

Abstract:

The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.

US Patent:

20200239963, Jul 30, 2020

Filed:

Sep 9, 2019

Appl. No.:

16/565422

Inventors:

- New York NY, US
Scott A. ARMSTRONG - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

C12Q 1/6886
A61K 31/5377
A61K 31/7064

Abstract:

Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication but who are nonetheless susceptible to treatment with DOT1L inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication with DOT1L inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a IIOX cluster gene or of a HOX cluster-associated gene. Elevated expression of such genes can be measured, e.g., by quantitating the relevant RNA and comparing it to that of a healthy individual (or cell) or to a predetermined standard or it can be inferred by determining whether the patient or cell possesses a mutation that is associated with elevated HOX cluster gene or HOX cluster associated gene expression and thereby inferring that the relevant expression with be elevated.

US Patent:

20190307750, Oct 10, 2019

Filed:

Jan 26, 2017

Appl. No.:

16/072876

Inventors:

- New York NY, US
Scott A. ARMSTRONG - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

A61K 31/519
A61P 35/02

Abstract:

Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.

US Patent:

20190270997, Sep 5, 2019

Filed:

May 10, 2019

Appl. No.:

16/409446

Inventors:

- New York NY, US
Eneda Toska - Edgewater NJ, US
Scott Armstrong - Wayland MA, US

Assignee:

MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY

International Classification:

C12N 15/113
A61K 31/4439
A61P 35/00

Abstract:

The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.

US Patent:

20160298195, Oct 13, 2016

Filed:

Aug 4, 2014

Appl. No.:

14/909713

Inventors:

- New York NY, US
Scott A. ARMSTRONG - New York NY, US

International Classification:

C12Q 1/68
A61K 31/5377
A61K 31/7064

Abstract:

Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication but who are nonetheless susceptible to treatment with DOT1L inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication with DOT1L inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a HOX cluster gene or of a HOX cluster-associated gene. Elevated expression of such genes can be measured, e.g., by quantitating the relevant RNA and comparing it to that of a healthy individual (or cell) or to a predetermined standard or it can be inferred by determining whether the patient or cell possesses a mutation that is associated with elevated HOX cluster gene or HOX cluster associated gene expression and thereby inferring that the relevant expression with be elevated.